Take-Two leans heavily on its next Grand Theft Auto release, with pre-orders and fresh updates expected soon—events that could quickly shift how investors see the business. The story also digs into what could go wrong if the launch slips again, and why the company’s wider lineup and in-game spending help soften the blow.Read more

Roche is lining up a new wave of potential hit medicines across obesity, cancer, and multiple sclerosis, with many important trial results expected soon. The big question is whether these programs succeed before tougher competition and upcoming patent expiries start to bite.Read more